19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 1
OA-12-Confronting TB stigma
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-12-Confronting TB stigma
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-12-569-22-Why is TB called the ‘disease of paper’? Exploring perceptions about the spread of TB in rural South Africa Understanding community perceptions of tuberculosis (TB) spread is valuable to informing clear communication during health visits. People diagnosed with TB can be subjected to ineffective and stigmatising TB infection control practices at home. Health workers need to proactively provide information to families and people diagnosed with TB in order to prevent discrimination.

Helene-Mari Van der Westhuizen

12:43 - 12:51: OA-12-570-22-Characterising TB stigma in the community: a mixed methods study in Cambodia While biomedical approaches, such as case detection and treatment, have contributed substantially to the country's fight against tuberculosis (TB), other social determinants of health, such as stigma, are not well understood in Cambodia. This study aimed to characterise and explore the determinants of TB stigma among people with TB in Cambodia.  

Sovannary Tuot

12:51 - 12:59: OA-12-571-22-TB-related stigma in urban communities in Uganda: what are the predictors? In Ugandan urban communities, tuberculosis (TB) related stigma was higher among TB patients (65.6%) compared to non-TB patients (49.8%). The risk factors included having HIV-related stigma, being below 50 years of age and being a TB patient or a TB patient with low TB knowledge. Stigma reduction interventions should target these for greater impact.

Timothy Kiyemba

12:59 - 13:07: OA-12-572-22-Gender differences in perceived TB stigma in Kampala, Uganda: a cross- sectional analysis Tuberculosis (TB) is stigmatised in many high burden settings. Perceived stigma prevents individuals from engaging with TB diagnostic and treatment services. Men and women may differ in perceptions of, or sensitivity to, TB-related stigma. We conducted a cross-sectional study of perceived TB-related stigma to compare perceptions of TB stigma by gender.

Amanda J Meyer

13:07 - 13:15: OA-12-573-22-A mixed methods assessment of stigma in people living with drug-resistant TB and HIV in South Africa We characterise drug-resistant TB (DR-TB)/HIV stigma among co-infected patients in KwaZulu-Natal, South Africa, as part of the PRAXIS (Prospective Study of Adherence in M/XDR-TB Implementation Science) study. The drivers and manifestation of internal and enacted stigma attributable to DR-TB and HIV are elucidated, compared and linked, using mixed methods.

Amrita Daftary

13:15 - 13:23: OA-12-574-22-“I hope we can do infection control in a more human way.” Balancing safety and stigma in rural South African health facilities Tuberculosis infection prevention and control (IPC) measures, such as masks and patient separation, may be stigmatising to patients. It is also critical for preventing the spread of TB in health facilities. Developing messaging that clearly explains TB IPC, and which emphasises communal wellbeing and safety, could assist with addressing TB stigma.

Helene-Mari Van der Westhuizen

13:23 - 13:31: OA-12-575-22-Funding human rights programmes in the TB response: the Global Fund experience Stigma and discrimination are most frequently identified human rights barriers to accessing tuberculosis (TB) services. However, there is little understanding of programmes in order to address such barriers and how to integrate those programmes in TB response. The Global Fund is committed to supporting programmes to address access barriers and there will be discussion on the lessons learned.

Hyeyoung Lim

13:31 - 13:39: OA-12-576-22-The development and validation of a scale to measure stigma around, and in people with, drug-resistant TB This is a cross-sectional study, conducted in Viet Nam, which evaluated 45 stigma-related items in order to develop the first multidrug-resistant tuberculosis stigma scale. Exploratory factor analysis was used for item reduction and psychometric analysis was conducted to assess the validity of the remaining 14-item scale. 

Lisa Redwood

13:39 - 13:50: Q&A


Loading...
Channel 4
OA-14-COVID-19: the great disrupter
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-14-COVID-19: the great disrupter
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-14-585-22-The contribution of asymptomatic SARS-CoV-2 infections to transmission: a model-based analysis of the Diamond Princess outbreak A key gap in the understanding of SARS-CoV-2 infection is the extent to which individuals, who are experiencing asymptomatic infections, contribute to transmission. We used a transmission model of COVID-19 to estimate the proportion, infectiousness and contribution to transmission of asymptomatic infections during the outbreak on the Diamond Princess cruise ship.

Jon C. Emery

12:43 - 12:51: OA-14-586-22-Effect of COVID-19 on TB patient notification in Japan To investigate the impact of COVID-19 spread on tuberculosis (TB) patients notification in Japan, we compared and analysed the numbers of newly notified TB cases in the first quarter of 2019 and 2020.

Kazuhiro Uchimura

12:51 - 12:59: OA-14-587-22-Contacts or care? Impact of COVID-19-related disruption on TB burden COVID-19-related disruptions could increase tuberculosis (TB) burden through negatively affecting health services and/or decrease transmission through reduced social contact. The impact on incidence may depend on the balance between these opposing factors. However, any benefit of distancing on the number of TB deaths, is likely to be outweighed by health service disruption.

Rebecca C. Harris

12:59 - 13:07: OA-14-588-22-The impact of the COVID-19 epidemic on active TB case finding interventions in Nigeria: the KNCV TB Foundation Nigeria experience The COVID-19 epidemic impacted negatively on the tuberculosis (TB) programme in Nigeria. Results from two core, active TB case finding interventions being implemented by KNCV TB Foundation Nigeria - the TB surge and WoW campaigns - showed a progressive decline in achievement from the onset of COVID-19 to date.  

Bethrand Odume

13:07 - 13:15: OA-14-589-22-Willingness to test for TB among symptomatic community members in an era of COVID-19: findings from an exploratory mixed methods study from Anambra State, Nigeria We explored the impact of the COVID-19 response on willingness to undergo a tuberculosis (TB) test at the community level. The language of communication of the COVID-19 interventions seemed to evoke fear among community members and negatively affected their willingness to do a TB test, despite having symptoms of TB. 

Chukwuebuka Ugwu

13:15 - 13:23: OA-14-590-22-Use of virtual and community-delivery platforms to prevent multidrug-resistant TB treatment interruption during the national COVID-19 response: lessons from Uganda COVID-19 came with unprecedented disruptions in the management of multidrug-resistant tuberculosis. This was particularly the case as a nationwide lockdown was announced, restricting community care of drug-resistant tuberculosis where over 80% of the patients are.

Enock Kizito

13:23 - 13:31: OA-14-591-22-Implementation of psychosocial support services for patients with TB during the quarantine regime due to COVID-19 In response to the emergency, the Ukraine national tuberculosis (TB) programme and the project quickly reformatted the implementation of services for patients with TB in order to ensure continuous access to anti-TB treatment and psychosocial support during the quarantine regime due to COVID-19.

Tanya Ismagilova

13:31 - 13:50: Q&A


Loading...
Channel 2
OA-13-The race for improved multidrug-resistant care
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-13-The race for improved multidrug-resistant care
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-13-577-22-Best practices in bedaquiline and delamanid use for rifampicin- resistant TB management: implementation of extension and combination use in 43 high burden countries Results from the #StepUpforTB 2020 study show 69% of countries recommend the combination use of bedaquiline and delamanid, while only 40% allow routine extension of either drug.  While policy recommendations for the newer drugs have included younger ages, adoption of best practices in bedaquiline and delamanid for adults remains slow.

Tiziana Masini

12:43 - 12:51: OA-13-578-22-The decentralised drug-resistant TB programme in South Africa: from policy to implementation A policy, supporting decentralised drug-resistant TB (DR-TB) treatment provision in South Africa, has had variable implementation. This paper examined how content, actors and processes of policy have interacted in context-specific ways to inform implementation. A better understanding of policy dynamics will contribute to lessons for strengthening future implementation of DR-TB policy.

Waasila Jassat

12:51 - 12:59: OA-13-579-22-Programmatic management of MDR/XDR-TB patients using the short treatment regimen from 2015 to 2019 in Cameroon Cameroon's programmatic management of rifampicin-resistant and multidrug-resistant tuberculosis (TB) patients, from 2015-2019, showed an 82% (505 out of 706) favourable outcome using the short treatment regimen. Out of 478 (68%) patients with documented data, moderate to severe auditory side effects (57/12%) remain the major challenge. We advocate for closer audiogram monitoring of patients receiving an injectable-base regimen.

Christelle G. Jouego

12:59 - 13:07: OA-13-580-22-Outcomes of a representative sample of patients lost to follow-up during drug-resistant TB treatment in the Philippines We identified additional mortality after tracing drug-resistant tuberculosis (TB) patients lost to follow-up from the Philippines National TB Control Programme. Strategies for retaining patients in care are critical to improving outcomes. Tracing should be considered for reporting accurate mortality data.

Alexander Rupert Lim

13:07 - 13:15: OA-13-581-22-Undiagnosed drug resistance in Mycobacterium tuberculosis is associated with higher mortality in countries with high TB burdens Accurate diagnosis is important in managing and controlling drug-resistant tuberculosis (TB) to reduce mortality. We compared results from drug resistance diagnoses clinics in countries with high TB burdens, against standardised culture-based testing and whole genome sequencing.

Martina L. Reichmuth

13:15 - 13:23: OA-13-582-22-Predominant yield of drug-sensitive TB among contacts of multidrug- resistant TB patients in Uganda: a call for next generation sequencing Contact investigation is one of the key, active tuberculosis (TB) case finding measures for early detection and treatment initiation in order to mitigate transmission and mortality due to delayed treatment. This abstract demonstrates the findings of a contact tracing cascade analysis for multidrug-resistant TB patients in a low-resource setting.

Kenneth Mutesasira

13:23 - 13:31: OA-13-583-22-Achieving high treatment success rate for drug-resistant TB following introduction of the novel, shorter treatment regimen Uganda adopted the novel, shorter multidrug-resistant TB (MDR-TB) treatment regimen following the 2016 World Health Organization MDR-TB treatment guidelines update. We share findings of a high treatment success rate among patients enrolled into the shorter regimen. 

John Paul Otuba

13:31 - 13:39: OA-13-584-22-Introducing facility-based mortality reviews into programmatic management of drug-resistant TB: lessons from Uganda We share findings of patient and health system factors that are contributing to multidrug-resistant tuberculosis patient mortality, following the introduction of facility-based death reviews into the programmatic management of drug-resistant TB in Uganda. 

John Paul Otuba

13:39 - 13:50: Q&A


Loading...
Channel 6
OA-16-TB Xpert in low- and middle-income countries: ensuring quality and quantity
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-16-TB Xpert in low- and middle-income countries: ensuring quality and quantity
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-16-598-22-Phased scale-up of external quality assurance for GeneXpert MTB/RIF testing under national TB elimination programme , India India's TB programme has rapidly scaled-up GeneXpert MTB/Rif testing, almost doubling the sites (628 to 1180), and testing has increased by five times (578173-2407211) from 2016 to 2018. To ensure a quality testing process, it strategically implemented External Quality Assurance (EQA) in a phased manner to monitor the quality of testing.

K Reena

12:43 - 12:51: OA-16-599-22-South Africa’s Xpert MTB/RIF Ultra external quality assurance experience: a need for good laboratory practice to minimise contamination South Africa's experience using external quality assurance in detecting contamination, due to Xpert® MTB/RIF Ultra’s increased sensitivity, and the need for improved good laboratory practice. A notable increase in the number of discordant results was analysed to advise on programme training needs and procedures to be reviewed for minimising contamination in routine settings.

Puleng Marokane

12:51 - 12:59: OA-16-600-22-Mentoring TB labs for improving and sustaining quality management system implementation and ISO 15189 accreditation: experiences from India The abstract focuses on experiences from India for improving and sustaining quality management system (QMS) implementation and ISO 15189 accreditation at 11 tuberculosis laboratories through mentoring support over the last three years

Tarak Shah

12:59 - 13:07: OA-16-601-22-A pilot study on the implementation of proficiency testing dried tube specimen production at a national public health laboratory: National Tuberculosis Laboratory, Kenya The external quality assurance panels enable facilities to identify diagnostic gas on time to enable continuity of quality services.
The Kenya National Tuberculosis Reference Laboratory demonstrated competency for panel production and managing the pilots, including corrective actions. These was made possible by mentorship from the US CDC, Atlanta, and the SRL, Uganda.

Solomon Bundi

13:07 - 13:15: OA-16-602-22-Role of GeneXpert technology in early detection of rifampicin-resistant TB in Afghanistan Elimination of tuberculosis (TB) is a major health priority for Afghanistan. Multidrug-resistant tuberculosis (MDR-TB) poses enormous challenges to health systems due to the complexity of diagnoses and treatment. For better diagnostic of presumptive MDR-TB patients, new bacteriologic-confirmed patients and extra-pulmonary TB, the national TB programme installed 49 GeneXpert machines.

Del Aqa Safi

13:15 - 13:23: OA-16-603-22-Overcoming barriers to GeneXpert optimisation in Nigeria: an analysis using the access concept GeneXpert optimisation is key to improving tuberculosis (TB) diagnosis, including rifampicin-resistant TB. However, Nigeria is yet to achieve the optimisation goal. This qualitative case-based study analyses barriers to effective GeneXpert optimisation using the ‘access concept’ and proposes proven health system and community strategies to surmount them.

Ogoamaka Chukwuogo

13:23 - 13:31: OA-16-604-22-The use of Xpert MTB/RIF in mobile vans: experience from Namibia A Namibian experience of using Xpert MTB/RIF instruments in mobile vans to demonstrate the feasiblility of use of these instruments in field-based screening activities. This demonstration proves that Gene X-pert can be utilised effectively outside routine laboratory settings to screen and diagnose drug-resistant tuberculosis (TB) in order to combat TB transmission.

Anita Beukes

13:31 - 13:50: Q&A


Loading...
Channel 5
OA-15-TB preventive therapy: we need to do better
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-15-TB preventive therapy: we need to do better
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-15-592-22-Reaching at-risk groups with TB preventive therapy: building on commitments made at the United Nations High Level Meeting By September 2018, Uganda's tuberculosis preventive therapy (TPT) coverage was very low. Following high-level leadership and stakeholder engagement, procurement of commodities and the establishment of a strong accountability mechanism for TPT results, the country has surpassed its United Nations High-Level Meeting TPT enrollment target for people living with HIV, with a 90% completion rate. 

Stavia Turyahabwe

12:43 - 12:51: OA-15-594-22-Uptake of isoniazid preventive therapy among newly diagnosed people living with HIV initiating antiretroviral therapy in South Africa: a post-hoc analysis of a cluster randomised trial Fourteen clinics were randomised to standard of care or Quantiferon-gold in-tube test for diagnosis of TB infection in newly diagnosed people living with HIV in North West, South Africa. We present a post-hoc analysis of isoniazid preventive therapy uptake among participants who initiated antiretroviral treatment within 30 days of study enrolment.

Kate Shearer

12:51 - 12:59: OA-15-595-22-Systems approach to improve TB preventive therapy outcomes among people living with HIV in resource-limited settings: experiences from East-Central Uganda Tuberculosis preventive therapy outcomes have been suboptimal, especially in sub-Saharan Africa, due to a combination of health system and patient-level barriers. A health system approach to address logistical, health workforce, service delivery barriers and patient level- barriers, using the quality improvement methodology, is critical in ensuring good completion rates.

Rodrigo Nyinoburyo

12:59 - 13:07: OA-15-596-22-Increasing access to TB preventive treatment for children under-five in Democratic Republic of Congo: preliminary results We documented lessons learned from the implementation of household contact investigation of children 0-14 years old, in collaboration with a local civil society organisation, in 21 health facilities in Kinshasa, Democratic Republic of Congo (DRC)

VICKY ILUNGA

13:07 - 13:15: OA-15-597-22-Interferon-gamma cytokine concentration levels as a biomarker for recent infection with Mycobacterium tuberculosis in an African community setting Tuberculosis preventive therapy is prioritised for latently infected groups at high risk for active disease. In a cohort study design, we determined that concentrations of interferon-gamma could serve as a biomarker to discriminate individuals that are recently infected with Mycobacterium tuberculosis from remotely infected persons with similar TST reading.

Samuel Kirimunda

13:15 - 13:42: Q&A


Loading...
Channel 7
OA-17-Safety first: side effects of old and new drugs
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-17-Safety first: side effects of old and new drugs
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-17-605-22-Audiometry outcomes during and after drug-resistant TB treatment with a kanamycin-containing drug-regimen: drug-resistant TB patients assessed in three rural districts of Masvingo Zimbabwe The abstract focuses on the ototoxic effects of a kanamycin-containing regimen on drug-resistant (DR-TB) patients managed in rural Zimbabwe without previous access to audiometry monitoring. Results show the importance of screening for drug side-effects during, as well as after, stopping the drug.

Cordelia Kunzekwenyika

12:43 - 12:51: OA-17-606-22-Validation study comparing tablet-based and conventional audiometry results in stage 2 of the STREAM trial Due to limited access to conventional audiometry testing in many high TB burden countries, tablet-based audiometry was used to monitor and evaluate for changes in hearing among multidrug-resistant tuberculosis trial participants. This validation study investigates the accuracy of tablet-based audiometry compared to conventional audiometry in stage 2 of the STREAM Trial.

Ishmael Qawiy

12:51 - 12:59: OA-17-607-22-Safety and efficacy of a shorter TB treatment: time to sputum culture positivity as a surrogate marker of bacterial load in an radomised control study of high-dose rifampicin and pyrazinamide Tuberculosis (TB) treatment is long, posing a risk of poor treatment adherence. In this randomised phase II study, we aim to investigate a strategy to shorten TB treatment by exploring safety, drug exposure and efficacy of a high-dose rifampicin/pyrazinamide regimen on early bactericidal activity using time to sputum culture positivity (TTP).

David Ekqvist

12:59 - 13:07: OA-17-608-22-Predictive analyses of QT prolongation from ECG monitoring in STREAM stage 1 The STREAM stage 1 trial investigated a short nine-month regimen for the treatment of multidrug-resistant tuberculosis, which included high-dose moxifloxacin and clofazimine, both of which can lead to QT prolongation. We analysed whether assessment of QT interval early on in treatment could be used to identify patients requiring more intensive QT monitoring.

Gareth Hughes

13:07 - 13:15: OA-17-609-22-A study to determine the frequency of QT interval prolongation in people treated with bedaquiline for drug-resistant TB Bedaquiline (BDQ) is a recent addition to the drug-resistant tuberculosis (DR-TB) armamentarium. There is a black-box warning of arrhythmias and sudden death associated with BDQ therapy. This retrospective study aimed to determine the incidence of QTc prolongation and cardiac events in patients receiving BDQ DR-TB therapy under routine conditions.

Sharon Isralls

13:15 - 13:23: OA-17-610-22-Pretomanid added to bedaquiline and linezolid for patients with extensively-drug resistant TB and multidrug-resistant TB treatment failure or intolerance: a comparison of prospective cohorts The Nix-TB study, evaluating the treatment of 109 patients with highly resistant TB with the oral 3-drug regimen (bedaquiline, pretomanid and linezolid; BPaL) for six-nine months, is compared to a cohort of contemporaneous patients, in South Africa, receiving regimens that included bedaquiline and linezolid, but not pretomanid.

Suzette Oelofse

13:23 - 13:31: OA-17-611-22-Moxifloxacin pharmacokinetics and cardiac safety in children with multidrug-resistant TB In this work, we characterise moxifloxacin pharmacokinetics and the exposure-response relationship with QT-interval prolongation in children 0-17 years. These results are from two observational pharmacokinetic and safety studies and provide important information regarding moxifloxacin use in young (<7 years) children and insight on optimal dosing.

Kendra K Radtke

13:31 - 13:50: Q&A


Loading...
Channel 3
SP-19-Household and close contact investigation: a key gateway to TB prevention and case detection in children
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-19-Household and close contact investigation: a key gateway to TB prevention and case detection in children
*Please scroll down for more information*
Children exposed to tuberculosis (TB) are at high risk of becoming infected and developing active TB disease. The World Health Organization recommends household TB contact investigation as routine public health practice. Scale-up of this intervention will be key to reach the End TB strategy and United Nations High-Level Meeting targets for paediatric TB case finding and prevention. Nevertheless, implementation of contact investigation remains challenging in TB-endemic countries. This session will review recent evidence on the effectiveness of contact investigation and TB preventive treatment (TPT) in children and discuss implementation approaches adapted for delivery in high-burden settings, including early implementer experiences on the roll-out of shorter TPT regimens.

12:30 - 12:35: Introduction

12:35 - 12:47: Assessing the risk of TB in children after close exposure: implications for implementation of contact investigation interventions in high TB burden countriesGlobally, tens of millions of children are exposed to an individual with tuberculosis (TB) annually. Drawing upon a multicohort collaboration of research groups, we aimed to explore two questions: i) estimating the risk of developing TB by time-period of follow-up, demographics (age, region), and clinical attributes (HIV, TB infection status, previous TB); and ii.) estimating the effectiveness of preventive therapy and BCG vaccination on the risk of developing TB. The results of this work will be presented in this session showing that the risk of developing TB among exposed infants and young children is very high and that most cases occurred within weeks of contact investigation initiation and might not be preventable through prophylaxis. Taken together, these findings suggest that alternative strategies for prevention are needed, such as earlier initiation of preventive therapy through rapid diagnosis of adult cases or community-wide screening approaches.
Leonardo Martinez

12:47 - 12:59: Implementation of contact investigation and TB preventive therapy provision in NepalBefore 2017, the Nepal national TB programme (NTP) mainly focused on passive case finding with limited active case finding activities. Contact tracing was implemented by the NTP in 38 high TB burden districts since early 2017. All household contacts undergo symptom screening and those screening positive are referred for tuberculosis (TB) evaluation, while children <5 without symptoms are referred for TB preventive therapy (TPT). Contact tracing of 27,982 bacteriologically-confirmed TB cases was done between March 2018 and December 2019.  There were 3,735 children initiated in TPT, with 96.8% retained in treatment (completing or still on treatment) and 3.2% discontinuing. Results have shown that contact tracing and a strong care cascade for TPT can be achieved in a low-resource setting, with an apparent immediate impact on TB outcomes. Programmes will be scaled-up throughout Nepal, through provision of adequate budget from both government and donors, maintaining routine supervision to ensure adherence and completion of TPT.
Suvesh Kumar Shrestha

12:59 - 13:11: Implementing household contact investigation in high TB burden, resource-limited settings: lessons learned from a multicountry project in nine sub-Saharan countriesContact investigation is recognised as an important intervention and it serves as a key entry point for both paediatric tuberculosis (TB) case finding and prevention. However, roll out and scale-up of contact investigation interventions remain challenging in high TB burden countries. The CaP TB project has implemented contact investigation interventions across nine sub-Saharan African countries and evaluated the cascade of care for both TB detection and TB preventive treatment. This presentation will review the evidence generated so far by the project, including early experiences on the use of the 3RH regimen under routine conditions, and discuss practical lessons learned on strategies and approaches that can improve implementation of contact investigation.
Martina Casenghi

13:11 - 13:23: Moving to shorter regimens for TB preventive treatment in children: current and future opportunitiesTuberculosis (TB) is a top cause of paediatric TB morbidity and mortality. Identifying recently exposed children and initiating TB preventive treatment (TPT) has been a longstanding approach to TB control. Short-course TPT has recently been endorsed by the World Health Organization and is an attractive solution to improving uptake and completion rates. There are many considerations for countries as they roll out short-course TPT for household child contacts and children and adolescents living with HIV. We will describe the current landscape for short-course TPT in both of these populations and highlight the gaps in our knowledge as they relate to paediatric dosing, drug interactions and efficacy. We will conclude with timelines for paediatric formulations for rifapentine and current research into 1HP and other novel short-course regimens.
Nicole Salazar-Austin

13:23 - 13:50: Q&A session

Loading...
Channel 1
P2-COVID-19: Major disrupter, new opportunities
event_note
Loading...
query_builder 14:00 - 15:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Plenary session
mic English
P2-COVID-19: Major disrupter, new opportunities
*Please scroll down for more information*
With over 36 million cases and 1 million deaths in early October, the COVID-19 pandemic, caused by the novel corona virus SARSCoV-2, brought the world to a halt in early 2020. Cities and countries retreated into varying degrees of social lockdown, economies plummeted and the medical and scientific fraternities scrambled to prepare and to uncover treatments and prevention strategies. How might we have been better prepared? What can we learn from our responses? And how can we use this opportunity to address historical inequalities that have been thrown into relief during this time?

14:00 - 14:03: Session introduction


14:03 - 14:18: PL2A-Lessons from the past and present for future pandemics

Michael T. Osterholm

14:18 - 14:23: PL2B-Global response to COVID-19

Maria Van Kerkhove

14:23 - 14:33: Impact of COVID pandemic on health care priorities and programmes

Madhukar Pai

14:33 - 14:48: PL2C-Human rights issues exposed

Allan Maleche

14:48 - 14:58: PL2D-Moderated panel discussion

Michael T. Osterholm
Madhukar Pai
Allan Maleche

Loading...
Channel 6
OA-20-The Union late-breaker session on COVID-19
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-20-The Union late-breaker session on COVID-19
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: LB-2100-22-Comparative evaluation of the clinical accuracy of SARS-CoV-2 serological rapid diagnostic tests and manual ELISAs The clinical accuracy of 25 commercially available SARS-CoV-2 antibody tests in five countries - Brazil, Italy, Spain, Switzerland and the USA - was determined. Our results suggest that the majority of antibody rapid diagnostic tests (RDT's) have insufficient sensitivity and specificity, but there are several high performing lab-based ELISAs that meet World Health Organization target product profile targets.

Jilian Sacks

15:13 - 15:21: LB-2093-22-Clinical accuracy, ease of use and limit of detection of SARS-CoV-2 antigen-detection rapid diagnostic tests The clinical performance, limit of detection and ease of use of six commercially available SARS-CoV-2 antigen rapid diagnostic tests was assessed in three countries - Brazil, the UK and Germany. Though there is substantial performance variability, our results suggest that at least two meet a minimum of 70% clinical sensitivity and 97% clinical specificity.

Jilian Sacks

15:21 - 15:29: LB-2090-22-High mortality among persons with comorbid rifampicin-resistant TB and COVID-19 in Khayelitsha, South Africa In April 2020, there were 181 active rifampicin-resistant tuberculosis (RR-TB) patients; 46 (25%) were tested for COVID-19 (n=22[48%] newly diagnosed) and 17 (37%) tested COVID-19 positive. Among those co-infected, eight (47%) died. Few newly diagnosed RR-TB patients were investigated for COVID-19 suggesting missed opportunities to detect COVID-19. Additionally, the mortality was high.

Erika Mohr-Holland

15:29 - 15:37: LB-2122-22-TB and COVID-19 co-infection among people with cough screened during active case finding of COVID-19 in the community with a high prevalence of TB This study shows the experience of screening for both tuberculosis and COVID-19 at the same time, using Xpert MTB/Rif and SARV-CoV-2 PCR tests, in the north of Lima during the programmatic activities on COVID-19 response in Peru.

Marco Tovar

15:37 - 15:45: LB-2113-22-Automated detection of COVID-19 in chest X-rays using deep learning for instant triage in hospital settings and integration with structured report generation Artificial intelligence screening of chest X-rays for COVID-19, integrating with structured reporting tools, can be an excellent tool for hospital triage to streamline workflows and hasten report turnaround time. It can act as a valuable auxiliary method for pre-screening symptomatic suspects and for providing final diagnostic reports with imaging, keeping experts in the loop.

Amit Kharat

15:45 - 15:53: LB-2051-22-Potential impact of the COVID-19 pandemic on essential TB services in Sri Lanka Common respiratory origin and interference with host immunity results in many clinical similarities between tuberculosis (TB) and COVID-19. Due to COVID-19, the Sri Lankan healthcare system is stretched beyond capacity. The catastrophic effect of COVID-19 on normality of the population and healthcare services has a negative impact on TB case detection.

Chathurani Mekala Wickramaarachchi

15:53 - 16:20: Q&A


Loading...
Channel 3
OA-19-Histories of success: improving TB and latent TB infection care
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-19-Histories of success: improving TB and latent TB infection care
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-19-619-22-Utility of stool CBNAAT in the diagnosis of paediatric pulmonary TB in India This study was conducted in New Delhi, India. It evaluated the utility of the stool CBNAAT test in paediatric pulmonary tuberculosis (TB). Results of stool CBNAAT were in near perfect agreement with Gastric aspirate CBNAAT results. This specimen could help in achieving microbiological confirmation in peripheral areas with a shortage of trained staff.

Anurag Agarwal

15:13 - 15:21: OA-19-620-22-Improving TB treatment outcomes: the role of the quality improvement approach: a case from Nairobi City County, Kenya Quality improvement (QI) plays a critical role towards attainment of the End TB Strategy goals, leveraging on already existing systems. This intervention demonstrates sustainable team-driven strategies that adopt a QI approach towards improvement of tuberculosis (TB) outcomes in the highest TB-burden county of Kenya.

Evelyn Nganga

15:21 - 15:29: OA-19-622-22-Use of intravenous isoniazid and ethambutol administration in patients with new sputum-positive, drug-susceptible pulmonary TB with tuberculous meningoencephalitis and HIV co-infection Fifty-four patients with TB-meningoencephalitis (TM) and HIV co-infection, were enrolled in this study. In TB-TM with HIV, intravenous isoniazid and ethambutol treatment was more effective than oral isoniazid and ethambutol at two months of intensive treatment. In addition, the mortality rate was lower in intravenously isoniazid and ethambutol treatment than oral.

Dmytro Butov

15:29 - 15:37: OA-19-623-22-When facility-based detection is not enough: increasing TB case detection through a social and behaviour change strategy in Nigeria The United States Agency for International Development's SHOPS Plus project created a social and behaviour change strategy, using geographic information systems (GIS) data, to hold community-led events in high tuberculosis (TB) burden communities where local healthcare providers and community leaders educate community members to seek care for TB symptoms and offer free TB screening and testing.

Ayodele Iroko

15:37 - 15:45: OA-19-624-22-Treatment uptake in people with TB detected by active case finding in Cà Mau Province, Viet Nam In the context of community-wide screening in rural province Cà Mau, Viet Nam, we estimate the proportion of tuberculosis screen-positive individuals who participate in each stage of the treatment cascade.

Boi Khanh Luu

15:45 - 15:53: OA-19-625-22-Analysis of large, patient-level dataset to predict outcome of treatment for patients with drug-sensitive and drug-resistant TB Drug-resistant tuberculosis (DR-TB) treatment is challenging and frequently leads to poor outcomes. NIAID TB Portals programme - an international collaboration focusing on DR-TB - collects, annotates and analyses patient-level data from multiple hospitals. We present a comprehensive machine learning analysis of patient characteristics, across diverse domains, associated with treatment outcome.

Qinlu Wang

15:53 - 16:20: Q&A


Loading...
Processing. Please wait.
Loading...